Adlai Nortye to Present AN4035 Preclinical Results at AACR-NCI-EORTC Conference

Adlai Nortye will present preclinical results of AN4035, a CEACAM5-targeting antibody-drug conjugate, at the AACR-NCI-EORTC International Conference. AN4035 demonstrated strong payload retention, potent cytotoxicity, and induced deep regression in CEACAM5-positive/RAS-addicted CDX and PDX models. It exhibited a favorable preliminary toxicology profile in cynomolgus monkeys. AN4035 was designed to address limitations of pan-RAS(ON) inhibitors by delivering a payload directly to tumors, reducing systemic toxicities.